Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed.
biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classes, and the biocrates metabolomics technology platform combines innovative sample preparation, metabolite identification, and data analysis.
The acquisition of biocrates further enhances Bruker’s MS-based metabolomics solutions. It also supports Bruker’s expansion into multiomics solutions, including instruments, reagents, software, and research services, building on the prior acquisitions of proteomics kits, software and services companies PreOmics and Biognosys.
Dr Oliver Rinner, Bruker’s Vice President for Enabling Multiomics Solutions and founder and CEO of Biognosys stated: “Multiomics is the cornerstone for the future of life sciences, biopharma R&D and clinical research, and biocrates adds key metabolomics solutions to the Bruker portfolio. With our services, software and kits for high-end proteomics and metabolomics we can now support customers with a truly integrated multiomics approach.”
“Our acquisition of biocrates represents a pivotal step in our ambitious metabolomics and lipidomics growth plans,” said Matt Lewis, Ph.D., Bruker Vice President, Metabolomics & Lipidomics. “By leveraging biocrates’ expertise in quantitation and workflow automation, we accelerate the impact of MS-based omics to revolutionize and advance a shared multiomics vision.”
Moritz Seuster, biocrates’ CEO, added: “Joining Bruker is a major milestone and a strong validation of our team’s hard work and vision. What makes this partnership so powerful is our shared passion for multiomics technologies and biocrates’ continued commitment to supporting and innovating across multiple MS technologies and vendors. With Bruker we’re poised to scale our impact while staying true to our mission to make omics quantitative, reproducible and easily accessible. We’re deeply thankful to our employees, customers, and partners who made this possible.”
Source: Other